Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture (Q31396053)

2 July 2017

title

Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture (English)

1 reference

2 July 2017

Sindermann JR

1

1 reference

2 July 2017

Fan L

2

1 reference

2 July 2017

Weigel KA

3

1 reference

2 July 2017

Troyer D

4

1 reference

2 July 2017

Müller JG

5

1 reference

2 July 2017

Schmidt A

6

1 reference

2 July 2017

March KL

7

1 reference

2 July 2017

Breithardt G

8

1 reference

2 July 2017

publication date

1 June 2000

1 reference

2 July 2017

1 reference

2 July 2017

volume

150

1 reference

2 July 2017

issue

2

1 reference

2 July 2017

page(s)

331-341

1 reference

The pathogenesis of atherosclerosis: a perspective for the 1990s

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Prevention of restenosis by lovastatin after successful coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Cell cycle-specific effects of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Translational control of p27Kip1 accumulation during the cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Biochemical properties and biological effects of p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Hyperplasia in multiple smooth muscle tissues in transgenic mice expressing a temperature-sensitive SV40 T-antigen under the control of smooth muscle alpha-actin regulatory sequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

A simple method for the flow cytometric analysis of intracellular antigens in whole smooth muscle cells: quantification of cyclin-dependent kinase 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Improved resolution of myofibrillar proteins with sodium dodecyl sulfate-polyacrylamide gel electrophoresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900393-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(99)00393-7

1 reference

2 July 2017

1 reference